Genomic Determinants of Early Recurrences in Low-Stage, Low-Grade Endometrioid Endometrial Carcinoma.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
14 11 2022
14 11 2022
Historique:
received:
17
01
2022
revised:
08
04
2022
accepted:
08
06
2022
pubmed:
15
6
2022
medline:
18
11
2022
entrez:
14
6
2022
Statut:
ppublish
Résumé
Low-stage, low-grade endometrioid endometrial carcinoma (EEC), the most common histologic type of endometrial cancer, typically has a favorable prognosis. A subset of these cancers, however, displays an aggressive clinical course with early recurrences, including distant relapses. All statistical tests were 2-sided. Using a combination of whole-exome and targeted capture sequencing of 65 FIGO stage IA and IB grade 1 EECs treated with surgery alone, we demonstrate that chromosome 1q gain (odds ratio [OR] = 8.09, 95% confidence interval [CI] = 1.59 to 54.6; P = .02), PIK3CA mutation (OR = 9.16, 95% CI = 1.95 to 61.8; P = .01), and DNA mismatch repair-deficient molecular subtype (OR = 7.92, 95% CI = 1.44 to 87.6; P = .02) are independent predictors of early recurrences within 3 years in this patient population. Chromosome 1q gain was validated in an independent dataset of stage I grade 1 EECs subjected to whole-exome sequencing. Our findings expand on the repertoire of genomic parameters that should be considered in the evaluation of patients with low-stage, low-grade EEC.
Identifiants
pubmed: 35699480
pii: 6608092
doi: 10.1093/jnci/djac119
pmc: PMC9664177
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1545-1548Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA247749 01
Pays : United States
Organisme : NCI NIH HHS
ID : P30CA008748
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Leuk Lymphoma. 2017 Aug;58(8):1823-1831
pubmed: 28078910
Gynecol Oncol. 2020 Dec;159(3):712-720
pubmed: 33046272
Gynecol Oncol. 2019 Jun;153(3):517-520
pubmed: 30910249
Annu Rev Genomics Hum Genet. 2011;12:25-51
pubmed: 21801020
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Int J Gynecol Pathol. 2022 May 1;41(3):207-219
pubmed: 34483300
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Int J Gynecol Cancer. 2020 Jun;30(6):717-723
pubmed: 32376737
Acta Neuropathol Commun. 2016 Aug 22;4(1):88
pubmed: 27550150
Neurosurgery. 2011 Jan;68(1):206-12
pubmed: 21099717
Mod Pathol. 2017 Jul;30(7):1032-1041
pubmed: 28281553
Int J Gynecol Cancer. 2020 Jun;30(6):783-788
pubmed: 32354793
J Gynecol Oncol. 2018 May;29(3):e39
pubmed: 29533022
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Int J Gynecol Pathol. 2020 Mar;39(2):119-127
pubmed: 30702464
J Clin Oncol. 2016 Sep 10;34(26):3189-94
pubmed: 27400937
Mod Pathol. 2022 Sep;35(9):1269-1278
pubmed: 35365770
N Engl J Med. 2020 Nov 19;383(21):2053-2064
pubmed: 33207095
Cancer. 2017 Mar 1;123(5):802-813
pubmed: 28061006
Lancet Oncol. 2014 Jun;15(7):e268-78
pubmed: 24872110
Neuropathol Appl Neurobiol. 2012 Apr;38(2):213-9
pubmed: 21988727
J Natl Cancer Inst. 2014 Sep 10;106(9):
pubmed: 25214561
Gynecol Oncol. 2006 Jun;101(3):520-9
pubmed: 16556457
Clin Cancer Res. 2017 Dec 1;23(23):7232-7241
pubmed: 28939739
J Natl Cancer Inst. 2017 Sep 1;109(9):
pubmed: 28376154